October 2025 in “Journal of Skin and Sexually Transmitted Diseases” Alopecia areata patients often have undetected thyroid issues, so routine thyroid screening is recommended.
September 2025 in “Meditsinskiy sovet = Medical Council” Atopic dermatitis significantly increases the risk of alopecia areata, especially in children.
September 2025 in “Journal of Skin and Stem Cell” The combination of calcipotriol and PRP is the most effective treatment for alopecia areata.
September 2025 in “Dermatology and Therapy” Baricitinib is a promising treatment for alopecia areata in the UAE, but there are challenges with data and access.
August 2025 in “American Journal of Clinical Dermatology” Clinicians should use evidence-based tools and consider mental health when assessing alopecia areata to guide treatment.
August 2025 in “Frontiers in Immunology” People with alopecia areata have a higher risk of heart disease.
July 2025 in “Pakistan Journal of Intensive Care Medicine” Clobetasol propionate 0.05% ointment is more effective than tacrolimus 0.1% ointment for treating alopecia areata.
July 2025 in “International Journal of Dermatology Venereology and Leprosy Sciences” Higher stress levels may worsen alopecia areata, suggesting stress management is important for treatment.
June 2025 in “International Journal of Science and Research (IJSR)” Tofacitinib effectively promotes hair regrowth in alopecia areata with minimal side effects.
March 2025 in “Pakistan Journal of Health Sciences” Intralesional steroids improve Alopecia Areata, and trichoscopy effectively tracks this improvement.
January 2025 in “SKIN The Journal of Cutaneous Medicine” Calcipotriol's effectiveness for treating alopecia areata is unclear and needs more research.
January 2025 in “Вопросы современной педиатрии” Janus kinase inhibitors effectively treat alopecia areata but may cause relapses and have long-term safety concerns.
January 2025 in “International Journal of Research in Medical Science” Homeopathy successfully treated complete hair loss in a man.
January 2025 in “Advances in Dermatology and Allergology” The Polish version of the Alopecia Areata Quality of Life Index is a reliable tool for assessing quality of life in Polish-speaking patients with alopecia areata.
January 2025 in “ARC Journal of Dermatology” Black patients are underrepresented in alopecia research, highlighting the need for more inclusive studies.
January 2025 in “Trepo - Institutional Repository of Tampere University” Alopecia areata significantly harms women's self-image, causing reduced confidence and social isolation.
December 2024 in “Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi” Both treatments are safe and effective, but anthralin may work better for some patients.
December 2024 in “Clinical Cosmetic and Investigational Dermatology” Alopecia areata might help slow down certain cancers.
October 2024 in “Journal of Education Health and Sport” Alopecia areata treatment should be personalized, using topical or systemic therapies based on severity, with promising options like JAK inhibitors needing more research.
October 2024 in “La Tunisie Médicale” Over half of alopecia areata patients in Tunisia experience depression, highlighting the need for psychological support.
September 2024 in “Drugs & Therapy Perspectives” Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
July 2024 in “Medical alphabet” The SBN system effectively assesses alopecia areata severity and predicts its course.
Baricitinib shows promise for treating alopecia areata with mild side effects.
April 2024 in “Frontiers in medicine” Alopecia Areata significantly lowers quality of life and current treatments are inadequate, highlighting a need for better therapies and standardized treatment protocols.
April 2024 in “Journal of asthma and allergy” Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.
March 2024 in “Dermatology and therapy” AA patients with comorbid conditions face more severe hair loss and need specific treatments.
February 2024 in “Scientific reports” Four genes are potential markers for hair loss condition alopecia areata, linked to a specific type of cell death.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
Donor lymphocyte infusions effectively treated leukemia relapse but caused vitiligo and alopecia areata.
January 2024 in “Frontiers in endocrinology” The study suggests that hypothyroidism may cause alopecia areata.